Literature DB >> 32676644

Management of non-culprit coronary plaques in patients with acute coronary syndrome.

Rocco A Montone1, Giampaolo Niccoli1,2, Filippo Crea1,2, Ik-Kyung Jang3.   

Abstract

Approximately 50% of patients with ST-segment elevation myocardial infarction (STEMI) have multivessel coronary artery disease, a condition associated with an increased incidence of recurrent ischaemic events and higher mortality. Based on recent evidences, a strategy of staged percutaneous coronary intervention (PCI) of obstructive non-culprit lesions should be considered the gold standard for the management of these patients. However, several issues remain still unresolved. Indeed, what is the optimal timing of staged PCI is not completely defined. Moreover, assessment of intermediate non-culprit lesions represent still a clinical conundrum, as pressure-wire indexes do not seem able to correctly identify those patients in whom deferral is safe. Intracoronary imaging may help to identify untreated non-culprit lesions containing vulnerable plaques that may portend a higher risk of future cardiovascular events. However, there are hitherto no studies demonstrating that preventive PCI of vulnerable plaques or more intensive pharmacological treatment is associated with an improved clinical outcome. In this review, we discuss the recent evolving concepts about management of non-culprit plaques in STEMI patients, proposing a diagnostic and therapeutic algorithm to guide physicians in clinical practice. We also underscore the several knowledge gaps to address in future studies. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Acute coronary syndrome; Fractional flow reserve; Non-culprit lesions; Optical coherence tomography; Precision medicine

Mesh:

Year:  2020        PMID: 32676644     DOI: 10.1093/eurheartj/ehaa481

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  Development and Evaluation of a Risk Prediction Model for Left Ventricular Aneurysm in Patients with Acute Myocardial Infarction in Northwest China.

Authors:  Yuanming Xing; Chen Wang; Haoyu Wu; Yiming Ding; Siying Chen; Zuyi Yuan
Journal:  Int J Gen Med       Date:  2022-07-06

2.  The long-term impact of a chronic total occlusion in a non-infarct-related artery on acute ST-segment elevation myocardial infarction after primary coronary intervention.

Authors:  Yu Liu; Le-Feng Wang; Xin-Chun Yang; Chang-Lin Lu; Kui-Bao Li; Mu-Lei Chen; Na Li; Hong-Shi Wang; Jiu-Chang Zhong; Li Xu; Zhu-Hua Ni; Wei-Ming Li; Kun Xia; Da-Peng Zhang; Hao Sun; Zong-Sheng Guo; Yong-Hui Chi; Ji-Fang He; Zhi-Yong Zhang; Feng Jiang; Hong-Jiang Wang
Journal:  BMC Cardiovasc Disord       Date:  2021-01-30       Impact factor: 2.298

3.  Coronary Computed Tomography Angiography Analysis of Calcium Content to Identify Non-culprit Vulnerable Plaques in Patients With Acute Coronary Syndrome.

Authors:  Théo Pezel; Georgios Sideris; Jean-Guillaume Dillinger; Damien Logeart; Stéphane Manzo-Silberman; Alain Cohen-Solal; Florence Beauvais; Niveditha Devasenapathy; Jean-Pierre Laissy; Patrick Henry
Journal:  Front Cardiovasc Med       Date:  2022-04-15

4.  The year in cardiovascular medicine 2021: interventional cardiology.

Authors:  Javier Escaned; Farouc A Jaffer; Julinda Mehilli; Roxana Mehran
Journal:  Eur Heart J       Date:  2022-02-03       Impact factor: 35.855

Review 5.  Current recommendations for revascularization of non-infarct-related artery in patients presenting with ST-segment elevation myocardial infarction and multivessel disease.

Authors:  Korakoth Towashiraporn
Journal:  Front Cardiovasc Med       Date:  2022-08-11

6.  The optimal timing for non-culprit percutaneous coronary intervention in patients with multivessel coronary artery disease: A pairwise and network meta-analysis of randomized trials.

Authors:  Yujia Feng; Shu Li; Sihan Hu; Jing Wan; Hua Shao
Journal:  Front Cardiovasc Med       Date:  2022-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.